Back to Authors

Drake, Bettina F.

https://orcid.org/0000-0001-9340-5848

Mayo Clinic

Washington University in St. Louis

Citations 3

NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023
Moses, Kelvin A. , Sprenkle, Preston C. , Box, Geoffrey N., Carlsson, Sigrid , Catàlona, William J. , Dahl, Douglas M. , Dall’Era, Marc , Davis, John W. , Epstein, Jonathan I. , Etzioni, Ruth B., Farrington, Thomas A., Garraway, Isla P. , Jarrard, David F. , Kauffman, Eric, Kaye, Deborah R. , Kibel, Adam S. , LaGrange, Chad A. , Maroni, Paul, Ponsky, Lee , Salami, Simpa S. , Shaneyfelt, Terrence, Smaldone, Marc C. , Sonn, Geoffrey A. , Tyson, Mark D. , Vapiwala, Neha , Wake, Robert, Washington, Samuel L. , Yu, Alice , Yuh, Bertram, Berardi, Ryan A., Freedman-Cass, Deborah A., Salami, Simpa S , Bahler, Clinton D. , Drake, Bettina F. , Etzioni, Ruth B., Reys, Brian D. , Sánchez, Alejandro , Seibert, Tyler M.

Journal of the National Comprehensive Cancer Network | March 10, 2023 | Volume: 21 | Issue: 3 | Pages: 236-246

10.6004/jnccn.2023.0014 Get It

The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.
Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network
Schuster, Anne L. R. , Crossnohere, Norah L. , Bachini, Melinda , Blair, Cindy K. , Carpten, John D. , Claus, Elizabeth B. , Colditz, Graham A. , Ding, Li , Drake, Bettina F. , Fields, Ryan C. , Janeway, Katherine A. , Kwan, Bethany M. , Lenz, Heinz‐Josef , Mishra, Shiraz I. , Ricker, Charité , Sussman, Andrew L. , Tiner, Jessica C. , Trent, Jeffrey M. , Verhaak, Roel G.W. , Wagle, Nikhil , Bridges, John F. P. , Network, for the Participant Engagement and Cancer Genome Sequencing (PE-CGS), Schuster, Anne Lr , Ma, Qin , Mishra, Shiraz I , Paskett, Electra D , Rebbeck, Timothy R , Ricker, Charité , Stern, Mariana Carla , Sussman, Andrew L , Tiner, Jessica C , Trent, Jeffrey M , Verhaak, Roel Gw , Wagle, Nikhil , Willman, Cheryl , Bridges, John Fp , Colditz, Graham A , Bachini, Melinda , Paskett, Electra D. , Rebbeck, Timothy R. , Willman, Cheryl L. , Network, for the Participant Engagement and Cancer Genome Sequencing (PE-CGS)

Cancer Epidemiology, Biomarkers & Prevention | February 15, 2023 | Volume: 32 | Issue: 4 | Pages: 487-495

10.1158/1055-9965.epi-22-0356 Get It

Abstract Background: Engaging diverse populations in cancer genomics research is of critical importance and is a fundamental goal of the NCI Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Established as part of the Cancer Moonshot, PE-CGS is a consortium of stakeholders including clinicians, scientists, genetic counselors, and representatives of potential study participants and their communities. Participant engagement is an ongoing, bidirectional, and mutually beneficial interaction between study participants and researchers. PE-CGS sought to set priorities in participant engagement for conducting the network's research. Methods: PE-CGS deliberatively engaged its stakeholders in the following four-phase process to set the network's research priorities in participant engagement: (i) a brainstorming exercise to elicit potential priorities; (ii) a 2-day virtual meeting to discuss priorities; (iii) recommendations from the PE-CGS External Advisory Panel to refine priorities; and (iv) a virtual meeting to set priorities. Results: Nearly 150 PE-CGS stakeholders engaged in the process. Five priorities were set: (i) tailor education and communication materials for participants throughout the research process; (ii) identify measures of participant engagement; (iii) identify optimal participant engagement strategies; (iv) understand cancer disparities in the context of cancer genomics research; and (v) personalize the return of genomics findings to participants. Conclusions: PE-CGS is pursuing these priorities to meaningfully engage diverse and underrepresented patients with cancer and posttreatment cancer survivors as participants in cancer genomics research and, subsequently, generate new discoveries. Impact: Data from PE-CGS will be shared with the broader scientific community in a manner consistent with participant informed consent and community agreement.